Compare KEN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | NAMS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | Singapore | Netherlands |
| Employees | N/A | 100 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2014 | N/A |
| Metric | KEN | NAMS |
|---|---|---|
| Price | $66.80 | $27.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 15.3K | ★ 883.5K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $9.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.50 | $21.23 |
| 52 Week High | $95.93 | $42.21 |
| Indicator | KEN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 35.97 |
| Support Level | $65.67 | N/A |
| Resistance Level | $71.01 | $37.29 |
| Average True Range (ATR) | 1.38 | 1.80 |
| MACD | 0.30 | -0.50 |
| Stochastic Oscillator | 46.79 | 9.74 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.